Zentalis Pharmaceuticals, Inc.

Aug 17, 2026

Zentalis Pharmaceuticals Announces Closing of Underwritten Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Zentalis Pharmaceuticals has successfully closed an underwritten public offering, raising approximately $92.6 million through the sale of 26.45 million shares at $3.50 each. The proceeds will be utilized for clinical trials, regulatory filings, and other corporate purposes. The offering was well-received, with the underwriters fully exercising their option to purchase additional shares.

Aug 14, 2026

▼ -14.2%on this newsshared move

Zentalis Pharmaceuticals Announces Pricing of Underwritten Public Offering

Zentalis Pharmaceuticals has announced the pricing of an underwritten public offering of 23 million shares at $3.50 each, aiming to raise around $80.5 million. The offering is set to close on August 17, 2026, and proceeds will be utilized for clinical trials, regulatory filings, and other corporate purposes. The company is advancing its WEE1 inhibitor, azenosertib, for ovarian cancer treatment.

Aug 13, 2026

▼ -14.2%on this newsshared move

Zentalis Pharmaceuticals Announces Proposed Underwritten Public Offering

Zentalis Pharmaceuticals announced a proposed underwritten public offering of its common stock, aiming to fund clinical trials and regulatory efforts for its WEE1 inhibitor, azenosertib, targeting ovarian cancer. The offering is contingent on market conditions, and the company plans to use the proceeds for various corporate purposes. Joint bookrunners for the offering include TD Cowen, Guggenheim Securities, and Oppenheimer & Co.

Zentalis Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Updates

Zentalis Pharmaceuticals reported its Q2 2026 financial results, highlighting significant progress in the development of azenosertib, a potential first-in-class WEE1 inhibitor for ovarian cancer. The company completed enrollment in DENALI Parts 2a and 2b and expects topline results in the first half of 2027. With $174.6 million in cash, Zentalis is well-positioned to advance its clinical trials and regulatory strategies.

Jul 17, 2026

Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026

Zentalis Pharmaceuticals announced two presentations at the ESMO Congress 2026, focusing on azenosertib's efficacy in treating platinum-resistant ovarian cancer. The rapid oral presentation will showcase overall survival data from the DENALI Part 1b study, while a trial-in-progress poster will detail the ASPENOVA Phase 3 study. These presentations underline Zentalis' commitment to advancing azenosertib as a treatment option for patients with high unmet needs.

Jun 2, 2026

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 1, 2026

Zentalis Pharmaceuticals announced the grant of non-qualified stock options for 191,000 shares to two new employees under its 2022 Employment Inducement Incentive Award Plan. This grant aligns with Nasdaq Listing Rule 5635(c)(4) and reflects the company's commitment to attracting talent. The stock options will vest over four years, contingent on continued employment.

May 27, 2026

Zentalis Strengthens Commercial Leadership with Appointments of Shannon Campbell to Board of Directors and Sarah Kelly as SVP of Commercial Strategy

Zentalis Pharmaceuticals has appointed Shannon Campbell to its Board of Directors and Sarah Kelly as Senior Vice President of Commercial Strategy. These appointments aim to bolster the company's commercial capabilities as it advances its investigational WEE1 inhibitor, azenosertib, through late-stage trials for Cyclin E1-positive platinum-resistant ovarian cancer. The company anticipates significant milestones in its registrational program.

May 21, 2026

▲ +11.6%on this newsshared move

Zentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026

Zentalis Pharmaceuticals announced promising data from the Phase 1b MUIR trial for azenosertib combined with paclitaxel in treating platinum-resistant ovarian cancer. The trial showed a 39% overall response rate and a median progression-free survival of 7.3 months. The combination demonstrated a manageable safety profile with low rates of high-grade adverse events, indicating potential for broader application in ovarian cancer treatment.

May 12, 2026

Zentalis Pharmaceuticals Reports First Quarter 2026 Financial Results and Clinical Progress

Zentalis Pharmaceuticals reported its financial results for Q1 2026, highlighting significant clinical progress with its investigational WEE1 inhibitor, azenosertib. The company selected a pivotal dose for its registration-intended trials and expects topline results from the DENALI Phase 2 trial by the end of 2026. Additionally, the ASPENOVA Phase 3 trial has commenced with the first patient dosed, aiming for full approval in Cyclin E1-positive ovarian cancer.

May 5, 2026

Zentalis Pharmaceuticals Announces First Patient Dosed in ASPENOVA Phase 3 Trial of Azenosertib in Patients with Cyclin E1-Positive Platinum-Resistant Ovarian Cancer

Zentalis Pharmaceuticals has initiated the Phase 3 ASPENOVA trial, dosing its first patient with azenosertib for Cyclin E1-positive platinum-resistant ovarian cancer. This trial aims to compare azenosertib to standard chemotherapy and supports the company's strategy for accelerated approval. The study is crucial for addressing the significant unmet needs in this patient population.

May 4, 2026

Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - May 1, 2026

Zentalis Pharmaceuticals announced the grant of stock options to a newly hired employee under its 2022 Employment Inducement Incentive Award Plan. The grant, totaling 26,000 shares, adheres to Nasdaq Listing Rule 5635(c)(4) and has an exercise price of $4.09 per share. The options will vest over four years, contingent on the employee's continued service.

May 1, 2026

Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Zentalis Pharmaceuticals announced the grant of 26,000 stock options to a new employee under its 2022 Employment Inducement Incentive Award Plan. This grant complies with Nasdaq Listing Rule 5635(c)(4) and is aimed at attracting talent to support its ongoing development of the WEE1 inhibitor azenosertib for ovarian cancer. The options have a 10-year term and will vest over four years.

Apr 17, 2026

▼ -7.6%on this news· ran to -24% by day 3

Zentalis Pharmaceuticals To Present Azenosertib Preclinical Data in Triple-Negative Breast Cancer and Real-World Analysis of Unmet Need in Cyclin E1-Positive Ovarian Cancer at AACR 2026

Zentalis Pharmaceuticals announced promising preclinical data on azenosertib, a WEE1 inhibitor, in triple-negative breast cancer (TNBC) and highlighted the significant unmet needs in Cyclin E1-positive ovarian cancer patients. The data will be presented at the AACR Annual Meeting 2026, showcasing azenosertib's potential to enhance treatment outcomes. The findings support expanding the drug's application beyond ovarian cancer.

Apr 9, 2026

▲ +60.1%on this news· ran to +139% by day 1

Zentalis Pharmaceuticals Announces 400mg QD 5:2 Azenosertib Monotherapy as the Pivotal Study Dose in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer

Zentalis Pharmaceuticals has selected 400mg QD 5:2 as the optimal monotherapy dose of azenosertib for Cyclin E1-positive platinum-resistant ovarian cancer based on interim analysis from DENALI Part 2a. This dose will be utilized in the ongoing DENALI Phase 2 and ASPENOVA Phase 3 trials. The company is also preparing for commercialization and expanding its clinical pipeline.

Apr 9, 2026

▲ +60.1%on this news· ran to +139% by day 1

zntlcorporateprese Corporate Presentation April 2026 Nasdaq: ZNTL 2 Zentalis Pharmaceuticals, Inc. ("we," "us," "our," "Zentalis" or the "Company") cautions that this presentation (including oral commentary that accompan

Zentalis Pharmaceuticals, Inc. presented details about its future plans for azenosertib, an investigational drug, including the anticipated momentum in its development program throughout 2026. The presentation highlighted the completion of enrollment in the DENALI Part 2a trial and alignment with FDA on the Phase 3 ASPENOVA trial design. Zentalis has a robust financial foundation with $245.9M in cash as of December 31, 2025. However, the company also acknowledged challenges including the potential for serious side effects and the need for additional funding.

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Zentalis Pharmaceuticals announced the grant of non-qualified stock options to two new employees as part of its 2022 Employment Inducement Incentive Award Plan. This grant, totaling 36,000 shares, aligns with Nasdaq Listing Rule 5635(c)(4) and reflects the company's commitment to attracting talent. The options have an exercise price of $2.57 per share and will vest over four years.

▼ -21.3%on this newsshared move

Mar 27, 2026

ZNTLFDA Updates

Zentalis Pharmaceuticals Reports Full Year 2025 Financial Results and Operational Updates

Zentalis Pharmaceuticals reported its financial results for 2025 and highlighted key milestones for 2026, including the completion of enrollment for the DENALI Part 2a trial. The company anticipates topline results from this trial by year-end, which could support accelerated approval for its WEE1 inhibitor, azenosertib. Additionally, Zentalis plans to initiate a Phase 3 trial, ASPENOVA, to compare azenosertib with standard chemotherapy.

Mar 18, 2026

▼ -7.9%on this news

Zentalis Pharmaceuticals to Present Two Posters at the American Association for Cancer Research (AACR) Annual Meeting 2026

Zentalis Pharmaceuticals announced two poster presentations at the AACR Annual Meeting 2026, showcasing their investigational WEE1 inhibitor, azenosertib. The presentations will highlight its potential as a combination therapy for Triple-Negative Breast Cancer and its biomarker-driven approach for ovarian cancer. This research aims to address significant unmet needs in cancer treatment.

Feb 18, 2026

Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences

Zentalis Pharmaceuticals announced its participation in upcoming investor conferences, showcasing its innovative WEE1 inhibitor, azenosertib, for ovarian cancer treatment. The company aims to enhance treatment experiences for patients with this first-in-class therapy. However, Zentalis faces challenges such as significant financial losses and uncertainties in clinical trial outcomes.

Feb 4, 2026

▼ -9.6%on this news· ran to -22% by day 1

Zentalis Pharmaceuticals to Participate in Upcoming February 2026 Investor Conference

Zentalis Pharmaceuticals will participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 11, 2026. The management team will discuss their investigational WEE1 inhibitor, azenosertib, which is being developed as a treatment for ovarian cancer. The event will be accessible via a live webcast, with recordings available for 30 days.

Aug 26, 2025

Zentalis Pharmaceuticals Appoints James B. Bucher, JD, as Chief Legal Officer and Corporate Secretary Seasoned life sciences legal executive brings extensive public company experience, including broad strategic and finan

Zentalis Pharmaceuticals announced the appointment of James B. Bucher, JD, as Chief Legal Officer and Corporate Secretary, effective September 18, 2025. Bucher, with over 30 years in the life sciences sector, brings considerable expertise in corporate strategy and legal compliance. He replaces Andrea Paul, who will transition to a role at a large law firm. The leadership expresses optimism that Bucher will aid in advancing the clinical development of azenosertib, a treatment for patients with ovarian cancer.

Jun 6, 2023

Zentalis Announces Intermittent Azenosertib Monotherapy Dosing Nearly Doubles Efficacy Over Continuous Dosing ORR of 36.8% in heavily pretreated platinum-resistant ovarian cancer and USC patients treated with intermitten

Zentalis Pharmaceuticals has announced favorable results for its azenosertib monotherapy, revealing that an intermittent dosing schedule nearly doubles efficacy in heavily pretreated patients with platinum-resistant ovarian cancer and uterine serous carcinoma. The recommended Phase 2 dose (RP2D) is now established at 400 mg daily, demonstrating an improved objective response rate of 36.8%. The new dosing strategy maintains safety and tolerability, with no treatment-related discontinuations reported. The company plans to provide further efficacy data and updates on ongoing Phase 2 trials in the latter half of 2023.

Jun 5, 2023

▼ -6.1%on this newsshared move

smith_asco2023xznx A Phase 1/2 Dose Escalation Study of the BCL-2 Inhibitor ZN-d5 and the WEE1 Inhibitor Azenosertib (ZN-c3) in Patients (Pts) With Acute Myeloid Leukemia (AML) Catherine Smith1, Pankit Vachhani2, Guiller

A Phase 1/2 dose escalation study is underway assessing the efficacy and safety of the BCL-2 inhibitor ZN-d5 combined with the WEE1 inhibitor azenosertib in patients with relapsed or refractory acute myeloid leukemia (AML). This study aims to establish the maximum tolerated dose and the clinical activity of this combination. Preliminary data suggest that both agents may work synergistically to enhance the efficacy of AML treatment. The study will enroll patients across seven sites in the United States and follow a rigorous treatment regimen.

Aug 12, 2021

Document Zentalis Pharmaceuticals Reports Second Quarter 2021 Financial Results and Operational Update Reported promising new interim data on both ZN-c3 and ZN-c5, highlighting their potentially best-in-class profiles Do

Zentalis Pharmaceuticals Reports Second Quarter 2021 Financial Results and Operational Update Reported promising new interim data on both ZN-c3 and ZN-c5, highlighting their potentially best-in-class profiles Dosed the first patient in a potentially registrational Phase 2 trial

May 17, 2021

Document Zentalis Pharmaceuticals Reports First Quarter 2021 Financial Results and Operational Update Reported robust initial results from the Phase 1 monotherapy dose escalation trial of its WEE1 inhibitor, ZN-c3, demon

Zentalis Pharmaceuticals Reports First Quarter 2021 Financial Results and Operational Update Reported robust initial results from the Phase 1 monotherapy dose escalation trial of its WEE1 inhibitor, ZN-c3, demonstrating single-agent activity and Exceptional Responses in heavily

Mar 25, 2021

Document Zentalis Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Update Initiated multiple early-stage clinical trials evaluating its oral SERD, ZN-c5, WEE1 inhibitor, ZN-c3 a

Zentalis Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Update Initiated multiple early-stage clinical trials evaluating its oral SERD, ZN-c5, WEE1 inhibitor, ZN-c3 and BCL-2 inhibitor, ZN-d5 Announced strategic collaboration with Te

Nov 9, 2020